Effect of intermittent treatment with human parathyroid hormone 1–34 in SAMP6 senescence-accelerated mice

被引:0
作者
Y. Washimi
H. Chen
A. Ito
R. Takao
T. Uzawa
Y. Yamamoto
H. Yamada
S. Shoumura
机构
[1] Fujita Health University,Department of Orthopedic Surgery
[2] Gifu University Graduate School,Department of Anatomy
[3] Pharmaceuticals Research Center,Laboratory for Development Pharmacology
[4] Asahi Kasei Pharma Corporation,Department of Physical Therapy
[5] Chubu Gakuin University Faculty of Rehabilitation,undefined
来源
Journal of Endocrinological Investigation | 2010年 / 33卷
关键词
BMD; cortical porosity; μCT; parathyroid hormone; SAMP6;
D O I
暂无
中图分类号
学科分类号
摘要
We examined trabecular and cortical bone in the senescence-accelerated mouse prone 6 (SAMP6) murine model of senile osteoporosis after treatment with human PTH 1–34. Sixteen-week-old female SAMP6 mice were assigned to control and PTH groups. PTH (20 μg/kg) was administered sc 3 times a week for 12 weeks. The control mouse strain, senescence-accelerated mouse resistant 1 (SAMR1), was used for comparison. The femoral metaphysis and diaphysis were used to measure bone mineral density (BMD), analyze the trabecular and the cortical structure by micro-computed tomography, and for conducting the bone strength test. PTH significantly attenuated the loss of BMD, improved the trabecular bone microstructure, and increased the bone strength in the femoral metaphysis. We did not find any differences in the bone strength of the femoral diaphysis after PTH treatment, although the cortical bone volume and cortical thickness were improved. Although the cortical thickness increased, the cortical bone density decreased, likely because of the increase of cortical porosity in the distal metaphysis after administration of PTH.
引用
收藏
页码:395 / 400
页数:5
相关论文
共 131 条
[1]  
Takeda T(1981)A new murine model of accelerated senescence Mech Ageing Dev 17 183-94
[2]  
Hosokawa M(1986)Age-related changes in bone mass in the senescence-accelerated mouse (SAM). SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis Am J Pathol 125 276-83
[3]  
Takeshita S(1995)Age-related decrease of nerve growth factor-like immunoreactivity in the basal forebrain of senescence-accelerated mice Acta Neuropathol 90 11-6
[4]  
Matsushita M(1997)Senescence-accelerated mouse (SAM): a novel murine model of senescence Exp Gerontol 32 105-9
[5]  
Tsuboyama T(2004)Consistency of low bone density across bone sites in SAMP6 laboratory mice J Bone Miner Metab 22 207-14
[6]  
Kasai R(1996)Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence J Clin Invest 97 1732-40
[7]  
Ohnishi K(2001)Chromosome 13 locus, Pbd2, regulates bone density in mice J Bone Miner Res 16 1972-82
[8]  
Tomimoto H(2002)A congenic mouse and candidate gene at the Chromosome 13 locus regulating bone density Mamm Genome 13 335-40
[9]  
Akiguchi I(2002)A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with osteoporosis J Clin Endocrinol Metab 87 4528-35
[10]  
Takeda T(2001)Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Eng J Med 344 1434-41